GlaxoSmithKline: Endometrial Neoplasms trials
The registry lists 13 Endometrial Neoplasms studies with GlaxoSmithKline as lead sponsor. 7 are open to participants now and 1 have results posted.
Phase 1 5Phase 2 5Phase 3 3Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingNCT07860450Phase 3
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)RecruitingNCT07684599Phase 3
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingNCT07652515Phase 4
- A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)RecruitingNCT07286331Phase 3
- A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsRecruitingNCT07213609Phase 1/2
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)RecruitingNCT07108270Phase 2
- A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)Not yet recruitingNCT06897527Phase 4
- Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial CancerCompletedNCT00267488Phase 2Results posted
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsActive, not recruitingNCT06710847Phase 1/2
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerActive, not recruitingNCT06317311Phase 2
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- Safety, Pharmacokinetics (PK) of AKT and MEK CombinationCompletedNCT01138085Phase 1
- A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795CompletedNCT00920257Phase 1